Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 8/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 2/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | ATF4 | P18848 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9301460 | 0.89 | CACNA1G (0.62) | CACNA1GKCNH2KMT2AATF4 | |
| SCHEMBL9300865 | 0.88 | KDM4E (0.53) | CACNA1GKCNH2KMT2A | |
| SCHEMBL9302021 | 0.88 | CYP2D6 (0.58) | CACNA1GKCNH2CYP2D6SCN1ASCN5A | |
| SCHEMBL9301208 | 0.87 | CYP2D6 (0.61) | CACNA1GKCNH2CYP2D6SCN1ASCN5A | |
| SCHEMBL9301158 | 0.86 | CACNA1G (0.67) | CACNA1GKCNH2CYP2D6KMT2ASCN1A | |
| SCHEMBL9301487 | 0.81 | CYP2D6 (0.55) | CACNA1GKCNH2CYP2D6SCN1ASCN5A | |
| SCHEMBL9301814 | 0.81 | CYP2D6 (0.54) | CACNA1GKCNH2CYP2D6KMT2ASCN1A | |
| SCHEMBL9192429 | 0.81 | KCNH2 (0.64) | CACNA1GKCNH2KMT2A | |
| SCHEMBL9187274 | 0.78 | MAPT (0.60) | CACNA1GKCNH2KMT2A | |
| SCHEMBL9271436 | 0.78 | CACNA1G (0.67) | CACNA1GKCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5342839-A | Useful for therapy of oxygen deficiency diseases of the brain | BASF AKTIENGESELLSCHAFT (DE) | 1994-08-30 | — | — | US | disclosed |
| EP-0435902-A1 | 2-HYDROXY-3-PHENOXY-PROPYL-SUBSTITUTED PIPERAZINES AND HOMOPIPERAZINES, THEIR MANUFACTURE AND USE. | BASF AG (DE) | 1991-07-10 | — | — | EP | disclosed |
| WO-1990003371-A1 | 2-HYDROXY-3-PHENOXY-PROPYL-SUBSTITUTED PIPERAZINES AND HOMOPIPERAZINES, THEIR MANUFACTURE AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1990-04-05 | — | — | WO | disclosed |